12Indexed trials
drug · Product Intelligence
Dexmedetomidine
Pipeline Intelligence
Dexmedetomidine: 12 indexed trials, 12 sponsors; 26 linked Orange Book patents and 12 FDA-linked events where matched.
12Sponsors
26Orange Book patent links
12FDA-linked events
Development evidence
NCT00345384Baylor Research Institute · depressionPHASE1, PHASE2
NCT01721460University of Wisconsin, Madison · parkinsonsPHASE4
NCT02256319Clinica Universidad de Navarra, Universidad de Navarra · parkinsonsPHASE4
NCT02607163Yonsei University · out_of_scopeNA
NCT02684019Theodor Bilharz Research Institute · out_of_scopePHASE3
NCT03067740Zagazig University · pain_neuropathyPHASE4
NCT03151863Walid HABRE · pain_neuropathyPHASE3
NCT03513757Medical College of Wisconsin · epilepsyPHASE4
NCT04675372China International Neuroscience Institution · other_neurologyPHASE4
NCT05743725Assiut University · neuro_oncologyNA
NCT06139692Jinling Hospital, China · strokePHASE4
NCT07801014Beijing Tiantan Hospital · anxietyNA
FDA / patent evidence
11998528IGALMI · app 2153902043-01-12
12364683IGALMI · app 2153902043-01-12
11806334IGALMI · app 2153902043-01-12
12138247IGALMI · app 2153902043-01-12
12090140IGALMI · app 2153902043-01-12
11998529IGALMI · app 2153902040-07-17
11890272IGALMI · app 2153902040-07-17
12109196IGALMI · app 2153902040-07-17
10792246IGALMI · app 2153902039-06-26
11478422IGALMI · app 2153902039-06-26
11497711IGALMI · app 2153902039-06-26
11517524IGALMI · app 2153902039-06-26
Regulatory context
FDA_EXCLUSIVITYIGALMI · M-822028-11-19
FDA_APPROVALDEXMEDETOMIDINE HYDROCHLORIDE · 2024-09-24
FDA_APPROVALIGALMI · 2022-04-05
FDA_APPROVALDEXMEDETOMIDINE HYDROCHLORIDE · 2021-09-03
FDA_APPROVALDEXMEDETOMIDINE HYDROCHLORIDE · 2020-12-07
FDA_APPROVALDEXMEDETOMIDINE HYDROCHLORIDE · 2020-09-15
FDA_APPROVALDEXMEDETOMIDINE HYDROCHLORIDE · 2020-06-12
FDA_APPROVALDEXMEDETOMIDINE HYDROCHLORIDE · 2017-11-28
FDA_APPROVALDEXMEDETOMIDINE HYDROCHLORIDE · 2017-05-12
FDA_APPROVALDEXMEDETOMIDINE HYDROCHLORIDE · 2017-04-26
FDA_APPROVALDEXMEDETOMIDINE HYDROCHLORIDE · 2015-08-20
FDA_APPROVALPRECEDEX · 2014-11-14
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.